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a b s t r a c t
Sulfation is a major pathway in humans for the biotransformation of steroid hormones and
structurally related therapeutic agents. Tibolone is a synthetic steroid used for the treat-
ment for climacteric symptoms and postmenopausal osteoporosis. Sulfation inactivates the
hydroxylated metabolites, 3-hydroxytibolone (3-OH-tibolone) and 3-hydroxytibolone
(3-OH-tibolone), and contributes to the regulation of tissue responses to tibolone. We
detected SULT1A1, SULT1A3, SULT1E1 and SULT2A1 mRNA expression by RT-PCR in post-
menopausal liver and small intestine. Liver pool (n = 5) SULT activities measured with
tibolone substrates reflected COS-1 expressed SULT2A1 and SULT1E1 activities. Liver
SULT2A1 activity (1.8 ± 0.3 units/mg protein, n = 8, mean ± SEM), and activities with 3-OH-
tibolone (0.6 ± 0.1, n = 8) and 3-OH-tibolone (0.9 ± 0.2, n = 8) were higher than SULT1E1 activ-
ities (<0.05, n = 10). SULT1E1 activities were low or not detected in many samples. Mean
small intestinal activities were 0.03 ± 0.01 with 3-OH-tibolone and 0.04 ± 0.01 with 3-OH-
tibolone (n = 3). In conclusion, SULT2A1 is the major endogenous enzyme responsible for
sulfation of the tibolone metabolites in human postmenopausal tissues. The results sup-
port the occurrence of pre-receptor enzymatic regulation of hydroxytibolone metabolites
and prompt further investigation of the tissue-selective regulation of tibolone effects.
© 2005 Elsevier Inc. All rights reserved.
1. Introduction
Tibolone (Livial) is a synthetic steroid that has been used
extensively for the prevention of postmenopausal osteoporo-
sis [1,2] and for the treatment of climacteric symptoms [3].
It is the prototype of a compound that acts as a selective
tissue estrogen activity regulator (STEAR) [4]. A key element
in this tissue specific regulation of estrogen activity is medi-
ated through enzymatic mechanisms that activate or inac-
tivate estrogenic compounds prior to their interaction with
a steroid receptor [5]. After oral administration, tibolone is
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metabolized into three biologically active metabolites. The
3-hydroxytibolone (3-OH-tibolone) and 3-hydroxytibolone
(3-OH-tibolone) metabolites have estrogen agonist proper-
ties, and the 4-ketoisomer has progestogenic and andro-
genic effects. Sulfation of the hydroxytibolone metabolites
by sulfotransferase enzymes (SULTs) renders these metabo-
lites receptor-inactive and reduces their estrogenic effects.
SULT activity may account for the clinical effects of tibolone
treatment that include an unchanged mammographic breast
density in most women, less symptoms related to the breast,
and less vaginal bleeding when compared with usual hor-
0039-128X/$ – see front matter © 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.steroids.2005.11.003
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mone replacement therapy [6–10]. An additional protective
effect of tibolone in these tissues is the inhibition of sulfatase
activity by the tibolone metabolites in breast and endometrial
cells [5,11]. By contrast, the lack of steroid SULT activity and
minimal inhibition of sulfatase activity by tibolone in bone
cells allow free hydroxytibolone metabolites to activate the
estrogen receptor () in bone and to decrease bone resorp-
tion [5,11]. Thus, tibolone, as a STEAR, does not behave as a
selective estrogen receptor modulator (SERM), but rather acts
by enzymatic pre-receptor regulation of the estrogenic active
metabolites.
Sulfated hydroxytibolone metabolites have been found in
the circulation, supporting the involvement of SULTs in the
regulation and metabolism of tibolone. In the cytosolic SULT
superfamily there are at least 10 human SULT genes [12].
Fusion proteins of two steroid SULTs expressed in bacteria
have been shown to use tibolone metabolites as substrates
[13]. However, the exact SULT isozymes involved in the sul-
fation of the active tibolone metabolites in postmenopausal
human liver and other tissues have yet to be fully character-
ized.
In this study we tested samples of human premenopausal
and postmenopausal liver and small intestine for SULT activi-
ties with tibolone metabolites. We then used postmenopausal
liver to establish biochemical properties and radiochemi-
cal assays with the substrates 3-OH-tibolone and 3-OH-
tibolone. These tools allowed us to document the post-
menopausal liver contribution to the sulfation of hydroxyti-
bolone metabolites. Because the cytosolic liver preparation
represented a composite of SULT activities, we also compared
the kinetic parameters of cDNA expressed SULT activities to




[35S] Phosphoadenosine-5-phosphosulfate ([35S]-PAPS, spe-
cific activity from 2.4 to 3.0 Ci/mmol) was purchased from
Perkin-Elmer LAS, Shelton, CT. 2-Difluoro-methyloestrone-3-
O-sulphamate (EMATE), the hydroxytibolone metabolites and
their respective sulfated compounds were provided by Dr. H.J.
Kloosterboer (Organon, Oss, The Netherlands). Dithiothreitol
(DTT) was purchased from CalBiochem, La Jolla, CA. Bovine
serum albumin (BSA), sodium chloride (NaCl), 2,6-dichloro-
4-nitrophenol (DCNP) and magnesium chloride (MgCl2) were
obtained from Sigma Chemical Company, St. Louis, MO. Pro-
tein assay reagent was obtained from Bio-Rad Laboratories,
Richmond, CA and Bio-Safe II scintillation fluor was purchased
from Research Products International Corp., Mount Prospect,
IL. COS-1 cells were obtained from the American Type Culture
Collection (ATCC), Rockville, MD. The human liver SULT1A1,
SULT1A2, SULT1A3, SULT1E1, SULT1C2, SULT2A1, SULT2B1 v1
and SULT2B1 v2 cDNAs were gifts from Dr. Weinshilboum
[14–18]. Trizol reagents, Superscript First-Strand Synthesis kit,
Lipofectamine, Platinum PCR Supermix kit were purchased
from Invitrogen Corp., Carlsbad, CA.
2.2. Tissue samples and cytosol preparations
Both the IRB and the Research and Development Commit-
tee of the VA-Nebraska Western Iowa Health Care System
approved these studies. Frozen human liver premenopausal
(37.8 ± 6.3 years, mean ± S.D., n = 5) and postmenopausal
(69.1 ± 7.4 years, mean ± S.D., n = 10) samples, and small intes-
tine premenopausal (39.2 ± 5.4 years, mean ± S.D., n = 5) and
postmenopausal (71 ± 10 years, mean ± S.D., n = 11) samples
were obtained from the National Disease Research Inter-
change (NDRI). All samples were obtained from Caucasian
subjects at autopsy except for one premenopausal liver sur-
gical sample and two premenopausal small intestine surgical
samples. Tissue was stored at −80 ◦C until preparation.
Tissue samples were homogenized for 15–30 s in four vol-
umes of 2.5 mM DTT, 1.25 mM disodium EDTA in 5 mM potas-
sium phosphate buffer, pH 7.5, with a Polytron Tissue Homog-
enizer (Kinematica, Lucerne, Switzerland). Homogenates were
centrifuged at 12,900 × g for 10 min at 4 ◦C. The supernatant
was removed and centrifuged at 100,000 × g for 1 h at 4 ◦C.
Aliquots of the high speed supernatant (HSS) were stored at
−80 ◦C until assay. Equal volumes of each HSS were pooled for
each tissue. COS-1 cells were transfected with SULT cDNA and
processed by our previously published procedures [19–22].
2.3. RNA extraction and RT-PCR
Total RNA was extracted from tissue using Trizol reagent
according to manufacturer’s instructions (Invitrogen). First
strand cDNA synthesis was performed using Superscript II RT
with oligo dT priming for 1 g total RNA by manufacturer’s
instructions. Each liver cDNA (87 ng), SULT1A1, SULT1E1 and
SULT2A1 plasmid cDNAs (1 ng) were used as the templates for
PCR with 0.1 nmol each SULT specific primers [21,23,24]. PCR
was performed using Platinum PCR Supermix (Invitrogen) and
an Eppendorf thermal cycler. Transcripts were amplified by an
initial denaturation at 94 ◦C for 2 min, followed by 35 cycles of
94 ◦C for 30 s, 55 ◦C (SULTs 1E1 and 2A1) or 65 ◦C (SULT1A1) for
1 min 15 s and 72 ◦C for 2 min. The PCR products were resolved
by 2% agarose gel electrophoresis and detected with ethidium
bromide.
2.4. Sulfotransferase (SULT) and protein assays
SULT activities were measured by the method of Foldes and
Meek [25], as modified by Anderson and Liebentritt [26].
Optimal conditions with hydroxytibolone as the substrate
were established with regard to pH, protein and substrate
concentrations. Assays with the hydroxytibolone substrates
were performed with 2.5 and 3.5 g protein per assay tube
for the liver pool HSS and the small intestinal HSS, respec-
tively. SULT1E1 and SULT2A1 were assayed with 1.1 and
0.7 g protein per assay tube, respectively. The final con-
centrations used in the assays were 1 M 3-OH-tibolone
and 4 M 3-OH-tibolone with liver and small intestinal HSS
and 1 M hydroxytibolone substrates for the activity screen
of expressed SULT enzymes. The pH values for potassium
phosphate buffers at a final concentration of 8.3 mM were 7.5
for the liver and small intestine, 6.5 for expressed SULT1E1
with hydroxytibolone, and 6.0 for expressed SULT2A1 with
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3-OH-tibolone and 7.0 with 3-OH-tibolone. A MgCl2 concen-
tration of 1.0 mM was used with hydroxytibolone metabolite
assays and 0.3 mM in assays with estrone (SULT1E1) and DHEA
(SULT2A1) as substrates. Assays of tissue SULT1A1, 1A3, 1E1
and 2A1 activities were performed with their respective model
substrates as previously published [19,27]. Reactions were
incubated at 37 ◦C for 30 min and blank samples containing
no sulfuryl group acceptor substrate were used as controls.
Radioactivity was measured using a Packard model 1600 TR
liquid scintillation counter. One unit of enzyme activity repre-
sented the formation of 1 nmol of sulfated product per hour of
incubation at 37 ◦C. Assays were performed in triplicate and
values reported are the means of three determinations unless
otherwise specified. Protein concentrations were measured
by the dye binding method of Bradford [28] with BSA as the
standard.
2.5. Thermal stability
Thermal stability of enzyme activities was tested by the meth-
ods of Reiter et al. [29] as modified by Anderson et al. [26,30].
Aliquots of diluted HSS were pre-incubated for 15 min at vari-
ous temperatures prior to assay. Aliquots of the same diluted
preparation were kept on ice as a control. Each aliquot was
then assayed for SULT activity.
2.6. HPLC
HPLC analyses were performed at room temperature using
a Waters RP18 3.5 M, 3.0 mm × 15 mm SymmetryShield col-
umn, a Beckman 126 solvent module, a 166 variable wave-
length detector and a Rainin 7725 manual injector. Sol-
vents were 0.1% (v/v) trifluoroacetic acid (TFA) in water (Sol-
vent A) and 0.1% (v/v) TFA in acetonitrile (ACN) (Solvent B).
Tibolone metabolites were separated with the following sol-
vent proportioning method: 0–5 min, 20% B; 5–30 min, 20–70%
B; 30–33 min, 70–20% B; and re-equilibration at 20% B. Flow rate
was 0.5 mL/min. Standard peaks were detected at 210 nm and
injections were 20 L with a Hamilton 25 L syringe. To con-
firm sulfation reaction products, each reaction mixture was
injected onto the column and fractions were collected at 1 min
intervals.
2.7. Data analysis
Apparent Km and Vmax values were calculated by the direct
linear plot method of Eisenthal and Cornish-Bowden [31]
using the Enzpak 3 program by Williams (Elsevier-Biosoft,
Cambridge, UK). The 50% inactivation temperature (T50), 50%
inhibition concentration (IC50) with DCNP and percentage of
increased activity with NaCl were determined using a curve-
fitting program. Linear regression analysis was done by the
Spearman rank correlation method for non-parametric statis-
tics (Prism3, GraphPad Software, San Diego, California).
3. Results
3.1. RT-PCR detection of human SULT expression
Reverse transcription-polymerase chain reaction (RT-PCR)
experiments were performed with total RNA extracted from
individual premenopausal and postmenopausal human liv-
ers and SULT gene-specific primers for SULT1A1, 1A3, 1E1,
2A1, 2B1 v1 and 2B1 v2. Liver and small intestinal samples
were tested to confirm whether mRNA predicted the presence
of activity for SULT1E1 and SULT2A1. SULT1A1, SULT1E1 and
SULT2A1 mRNAs were expressed in all 10 postmenopausal
liver samples (Fig. 1). In separate studies of mRNA expres-
sion, SULT1A3 was present in all liver samples and SULT2B1 v2
mRNA was expressed in seven samples, while SULT2B1 v1
mRNA was not detected in any of the liver samples (data
not shown). Six individual postmenopausal small intestinal
samples were tested as a representative sampling. All were
positive for SULT1A1, five of six were positive for SULT1A3 and
only two samples were both positive for SULT1E1, SULT2A1
and SULT 2B1 v2 (data not shown).
3.2. Postmenopausal human liver SULT activities with
tibolone metabolites
A pool of the postmenopausal liver HSS was used to charac-
terize SULT activities with hydroxytibolone substrates. Human
liver SULT activities with hydroxytibolone increased in a lin-
ear fashion with HSS protein up to at least 25 g protein per
Fig. 1 – RT-PCR of SULT2A1, SULT1E1 and SULT1A1 expression in individual premenopausal and postmenopausal liver
tissues. SULT1A1 expression was used as an internal standard. One microgram extracted total RNA from each liver tissue
was converted to cDNA and used as the template for PCR with SULT-specific primers as described in Section 2. The first lane
on the left is the 100 base pair ladder with 300, 200 and 100 bp bands from the top to the bottom of each gel image. PCR
products were separated by 2% agarose gel electrophoresis and visualized with 0.01% ethidium bromide and ultraviolet
light.
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Km (M) 0.18 ± 0.05 0.48 ± 0.14
Vmax (units/mg protein) 1.22 ± 0.04 4.9 ± 0.2
Expressed SULT2A1
Km (M) 0.79 ± 0.12 0.56 ± 0.09
Vmax (units/mg protein) 2.1 ± 0.2 5.9 ± 0.4
Postmenopausal liver SULTs
Km (M) 0.18 ± 0.04 0.42 ± 0.07
Vmax (units/mg protein) 0.9 ± 0.1 1.3 ± 0.2
PAPS Km (M) 0.060 ± 0.002 0.060 ± 0.004
PAPS Vmax (units/mg protein) 1.40 ± 0.02 1.81 ± 0.03
T50 (◦C) 43.2 ± 0.5 43.1 ± 0.3
DCNP IC50 (M) 190 ± 50 180 ± 15
Activation by NaCl (%) 46.1 ± 4.8 54.6 ± 7.5
Results are expressed as the mean ± SEM of three experiments, each
performed with triplicate determinations except for the T50 and
DCNP studies each performed with six determinations from two
experiments.
assay. The chosen final HSS protein of 2.5 g was within the
linear range of activity. Optimal SULT activities were found
with potassium phosphate, pH 7.5. Magnesium increases the
activities of several SULT enzymes [15,19]. Therefore, MgCl2
concentrations of 1.0–16 mM were tested in the assay. A final
MgCl2 concentration of 1.0 mM increased SULT activities by
9.2% with 3-OH-tibolone and by 6.2% with 3-OH-tibolone.
Subsequent liver and small intestine SULT assays with hydrox-
ytibolone were performed at pH 7.5 with 1.0 mM MgCl2.
3.3. Effects of varying hydroxytibolone and PAPS
concentrations
The effect of a range of hydroxytibolone concentrations on
SULT activities was determined (Fig. 2). When hydroxyti-
bolone concentrations were evaluated from 16 pM to 128 M,
substrate inhibition occurred at concentrations above 2 M
3-OH-tibolone and 4 M 3-OH-tibolone. Apparent Km val-
ues for postmenopausal human liver SULTs with hydroxyti-
bolone were calculated from the means of three experiments
with each substrate (Table 1). The optimal concentrations of
hydroxytibolone used in subsequent assays of liver and small
intestine SULTs were 1 M 3-OH-tibolone and 4 M 3-OH-
tibolone.
The effect of varying [35S]-PAPS concentrations on SULT
activities was determined with constant concentrations of
1 M 3-OH-tibolone and 4 M 3-OH-tibolone. A [35S]-PAPS
concentration of 0.4 M was used in all assays.
3.4. Effects of temperature, DCNP inhibition and
sodium chloride
Assays were conducted to compare the thermal stability, DCNP
inhibition and the effect of NaCl on postmenopausal human
liver SULT activities with hydroxytibolone substrates. Thermal
stability is a sensitive indicator of differences in protein struc-
Fig. 2 – Double reciprocal plots with hydroxytibolone
substrates. Panel A: Effects of varying 3-hydroxytibolone
() and 3-hydroxytibolone (©) substrate concentrations on
sulfation by postmenopausal human liver SULT activities.
Each data point represents the mean ± SEM of three
experiments, each performed with triplicate
determinations. Panel B: Effects of varying the
3′-phosphoadenosine-5′-phosphosulfate (PAPS)
co-substrate concentrations on the sulfation of 1 M
3-OH-tibolone () and 4 M 3-OH-tibolone (©) by
postmenopausal human liver SULT activities. Each data
point represents the mean ± SEM of six determinations
from two experiments.
ture [29]. The patterns of tissue SULT thermal stability when
assayed with tibolone might indicate which isozyme was
involved. The thermal stability of human liver SULT activities
was determined with hydroxytibolone after pre-incubation of
tissue aliquots for 15 min at temperatures from 35 to 47 ◦C
(Table 1).
Another approach to the characterization of SULT isozymes
is the response to the inhibitor DCNP. Human postmenopausal
liver SULT activities assayed with hydroxytibolone were mea-
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Fig. 3 – Expressed SULT activities with 1 M
3-hydroxytibolone and 3-hydroxytibolone metabolites as
substrates. The presence of SULT activities in the expressed
preparations was tested with appropriate substrates for the
enzymes. SULTs 2B1a and 2B1b represent 2B1-V1 and
2B1-V2, respectively.
sured with various concentrations of DCNP (Table 1). IC50
values for SULT activities with DCNP were similar. NaCl
enhances SULT1E1 and SULT2A1 activities when assayed with
the model substrates estrone and DHEA [15,19]. In our study,
activation was present when the postmenopausal human
liver pool was assayed with hydroxytibolone as the substrates
in the presence of NaCl (Table 1). The activation was consistent
with the behavior of steroid SULTs 1E1 and 2A1, as opposed to
inhibition by NaCl that occurs with SULT1A1 and SULT1A3 [27].
3.5. Expressed SULT activity with tibolone metabolites
Expressed SULT1E1 and SULT2A1 demonstrated excellent
activities when screened with assays using 1 M hydrox-
ytibolone as the substrates. Expressed SULT1A1, SULT1A2,
SULT1A3, SULT1C2, SULT2B1 v1 and SULT2B1 v2 assayed with
the same substrates showed no detectable activities (Fig. 3).
Further investigation of expressed SULT1E1 and SULT2A1 was
done to determine optimal assay conditions and apparent Km
values with the tibolone metabolites (Table 1). These values
were equivalent to the apparent Km values obtained with the
postmenopausal liver preparations.
3.6. Product identification by HPLC
Radiolabeled hydroxytibolone products were prepared with
the optimized assay, separated with reversed phase HPLC and
compared to standards. The radiolabeled products of sulfa-
tion by postmenopausal liver SULTs, expressed SULT1E1 and
SULT2A1 co-eluted with the 3-sulfate-hydroxytibolone stan-
dards exclusively when 3-OH-tibolone was the substrate. A
major product peak that was produced when 3-OH-tibolone
was assayed with each SULT preparation co-eluted with the
3-sulfate-hydroxytibolone standard. In assays with only the
liver and expressed SULT2A1 there was a second smaller peak
that was not identified because it did not co-elute with any of
the available standards.
3.7. Individual liver activities with tibolone
metabolites
To assess the tissue specific activity of liver SULTs and
their contributions to sulfation of tibolone metabolites, indi-
vidual premenopausal and postmenopausal liver samples
were assayed with 25 nM estrone (SULT1E1), 5 M DHEA
(SULT2A1), 1 M 3-OH-tibolone and 4 M 3-OH-tibolone
as the substrates. (Figs. 4 and 5). Activities with the pre-
menopausal livers were 0.6 with estrone (n = 2), 3.1 ± 0.8 with
DHEA (n = 5), 2.9 ± 0.9 with 3-OH-tibolone and 4.0 ± 1.3 with
3-OH-tibolone (both n = 5, units/mg protein, mean ± SEM,
Fig. 4). Each activity measured with DHEA or hydroxyti-
bolone as the substrates was higher than the activity with
estrone. SULT activities of the postmenopausal livers were
<0.05 (n = 10) with estrone (SULT1E1), 1.8 ± 0.3 (n = 8) with
DHEA (SULT2A1), 0.6 ± 0.1 and 0.9 ± 0.2 with 3-OH-tibolone
and 3-OH-tibolone, respectively (n = 8) (units/mg protein,
mean ± SEM, Fig. 5). Samples with undetectable SULT1E1
activity were tested with EMATE, a sulfatase inhibitor. Sul-
fatase activity would degrade the radiolabeled product and
obscure the presence of SULT activity. There were no increases
in measured SULT1E1 activity in the presence of EMATE. In
addition, there was no relationship between the SULT1E1 tis-
sue activities and time from death to autopsy to explain loss of
activity, but the sample number was small (data not shown).
The internal liver standard used to monitor SULT1E1 assays
was a pool of samples from three male donors. The SULT1E1
activity was several-fold higher than postmenopausal sam-
ples and the liver HSS pool stored at −80 ◦C retained activity
throughout the 2 years of this study.
3.8. Small intestine activities with tibolone metabolites
Human gastrointestinal tissue contains multiple SULT
enzymes that include SULTs 1A1, 1A3, 1E1 and 2A1 [32].
These enzymes are differentially distributed throughout the
gut [33] and they contribute to the metabolism of hydrox-
ytibolone metabolites within the intestine. We tested both
premenopausal and postmenopausal small intestinal HSS
samples for SULT activities in pooled preparations with the
same substrate concentrations used with the liver samples.
SULT1A1 activities of 2.7 and 0.2 units/mg protein were present
in premenopausal and postmenopausal samples, respectively,
and SULT1A3 activities were 12.8 and 0.2 units/mg protein
with premenopausal and postmenopausal samples, respec-
tively. Activities with the premenopausal small intestinal pool
(n = 4) were <0.1 units/mg protein with estrone (SULT1E1) and
0.2 units/mg protein with DHEA (SULT2A1). Activities with
the postmenopausal small intestinal pool (n = 6) were not
detectable with estrone or DHEA. Mean activities of three
individual samples with measurable levels were 0.03 ± 0.01
with 3-OH-tibolone and 0.04 ± 0.01 with 3-OH-tibolone
(units/mg protein, mean ± SEM). It was not possible to deter-
mine the exact location of the intestinal tissue samples to
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Fig. 4 – Individual premenopausal liver SULT activities assayed with 1 M 3-hydroxytibolone (Panel A), 4 M
3-hydroxytibolone (Panel B), 5 M dehydroepiandrosterone (DHEA) (Panel C) and 25 nM estrone (E1) (Panel D with lower
activity scale). Activities with hydroxytibolone substrates represent a composite of liver SULT activities (Panels A and B).
Results with substrates estrone and DHEA indicate SULT1E1 and SULT2A1 activities, respectively. Each bar represents the
mean of three determinations.
discern whether the sampling itself contributed to the differ-
ences observed. The mean SULT2A1 activity of the two pre-
menopausal surgical small intestine samples was similar to
the higher SULT2A1 activity of one of the three premenopausal
autopsy samples. Other premenopausal surgical small intesti-
nal SULT activities showed no distinct patterns that distin-
guished them from autopsy small intestinal sample activities.
In these small groups, there were no trends of negative corre-
lations between SULT activities and length of time from death
to autopsy in liver or small intestine (r = 0.0, n = 8 for post-
menopausal livers; no meaningful trend was evident for the
three small intestinal samples with activity).
4. Discussion
Tibolone represents the initial steroid in the class of agents
identified as selective tissue estrogen activity regulators
(STEAR) [4]. This study is the first systematic investigation of
human postmenopausal tissue sulfation of tibolone metabo-
lites as one of the tissue-specific components in the pre-
receptor enzymatic regulation of the estrogenic effects of
tibolone. We have identified human premenopausal and post-
menopausal liver and small intestine SULT activities involved
in the sulfation of the hydroxytibolone metabolites. Assays
established for these activities represented a combination
of SULT activities because of the documented presence of
multiple SULTs in these tissues [32–34]. Biochemical proper-
ties found for postmenopausal liver SULTs with the tibolone
metabolites as substrates were similar to those described
with cDNA-expressed human SULT1E1 and SULT2A1 activi-
ties (Table 1). For example, the apparent Km values for the
postmenopausal liver SULTs and expressed SULT1E1 with 3-
OH-tibolone as the substrate were 0.18 M for each prepara-
tion. Apparent Km values for all three preparations assayed
with 3-OH-tibolone were essentially the same, from 0.42 to
0.56 M. The individual liver activity data and HPLC analyses
of assay products with normal and postmenopausal livers and
expressed SULT preparations indicated that SULT2A1 was the
major contributor to the sulfation of 3-OH-tibolone and 3-
OH-tibolone.
Liver SULT2A1 activities measured with DHEA as the sub-
strate varied 3.7-fold in the premenopausal samples and
23-fold in the postmenopausal samples. Previous studies of
human female surgical samples have documented a four-fold
variation in liver SULT2A1 activity [34] and a 15-fold varia-
tion in small intestine SULT2A1 immunoreactive protein [32].
Genetic polymorphisms of SULT2A1 associated with decreased
activity have been described only in African American subjects
[35]. Effects of such polymorphisms are unlikely in our sam-
ples because they were all obtained from Caucasian subjects.
Other reasons for SULT2A1 variability in our samples include
changes in activity due to sample handling prior to assay or
differences in sample location within the small intestine that
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Fig. 5 – Individual postmenopausal liver SULT activities assayed with 1 M 3-hydroxytibolone (Panel A), 4 M
3-hydroxytibolone (Panel B), 5 M dehydroepiandrosterone (DHEA) (Panel C) and 25 nM estrone (E1) (Panel D with lower
activity scale). Activities with hydroxytibolone substrates represent a composite of liver SULT activities (Panels A and B).
Results with substrates estrone and DHEA indicate SULT1E1 and SULT2A1 activities, respectively. Each bar represents the
mean of three determinations.
would reflect the variable distribution of SULT activities within
the gastrointestinal tract [33]. There were no trends to sup-
port an association of SULT2A1 activities with the length of
time from death to autopsy in our limited number of liver and
small intestinal samples. However, the ability to accurately
designate the location of the small intestinal sample acqui-
sition supported the use of surgical tissue in future studies.
The potential effects, if any, of SULT2A1 activity variations
upon intra-hepatic or small intestinal regulation of responses
to hydroxytibolone metabolites are not known.
Individual liver SULT1E1 activities were low in both pre-
menopausal and postmenopausal samples. Two of the five
premenopausal samples contained substantial SULT1E1 activ-
ity and four of the 10 postmenopausal samples contained
SULT1E1 activity that was just above the limit of detection
for the assay (Figs. 4 and 5). SULT1E1 activity was unde-
tectable in the remaining samples. Reasons other than sample
handling for the variations include SULT1E1 genetic polymor-
phisms that lead to decreased enzyme activity and immunore-
active protein [36] or alterations in the tissue hormonal
environment [37]. Our samples were not genotyped for the
SULT1E1 allozymes, but this approach in a larger sample
of postmenopausal tissues might assist in explaining varia-
tions. Changes in SULT1E1 levels have been documented in
endometrial tissue as a result of cycling progesterone in pre-
menopausal women and also in women on oral contraceptives
that contain progestational agents [37,38]. To address the pos-
sibility that the SULT1E1 activities in liver and small intes-
tine might change with the variations in the local hormonal
milieu, future studies of these tissues from women will require
detailed information about their hormonal status.
This report has established the radiochemical enzymatic
assay for human postmenopausal liver SULT activities with
hydroxytibolone substrates, characterized the SULT biochem-
ical properties with these substrates and identified SULT2A1
as the major contributor to sulfation of these metabolites in
postmenopausal tissue. Our documentation of the tissue SULT
activities and the resulting sulfated hydroxytibolone metabo-
lites supports the occurrence of pre-receptor enzymatic reg-
ulation of estrogen compounds. The results provide a basis
for further investigation of the tissue-selective regulation of
tibolone effects and emphasize the complexity of steroid hor-
mone sulfation.
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